Incidence and Prevalence of Neuroendocrine Tumors (NETs) of the Ileum and Colon (Excluding Appendiceal NETs) in Northern Ireland (NI) Over a 25-Year-Period (1988-2012) Abstract #876

Introduction: Incidence of NETs is quoted to be 2/100,000 with approximately 25% being tumors of the midgut, (0.5/100,000). Incidence is increasing. However, this may be in part due to improved diagnosis but it is also thought to be a true increase.
Aim(s): To establish incidence and prevalence of MGC in NI and to identify trends over 25 years.
Materials and methods: We have interrogated the Northern Ireland Cancer Registry, NET specialist clinic registry, pathology laboratory reports and clinical chemistry laboratory reports, and clinical records to identify patients diagnosed with MGC diagnosed or current between 1/1/1988 and 31/12/2012. Diagnosis using pathology reports or using biomarkers with syndrome and/or positive somatostatin scintigraphy was accepted. Population in NI 1988-2012 has been obtained from population census data.
Conference: 11th Annual ENETS Conference (2014)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Professor Joy E Ardill
Keywords: MGC

To read results and conclusion, please login ...

Further abstracts you may be interested in

#669 Incidence of Second Malignancy in Patients with Neuroendocrine Tumors (NETs) of the Ileum and Colon (MGC)
Introduction: Increased incidence of second malignancy is observed in NETs (Kamp et al 2012).
Conference: 10th Annual ENETS Conference (2013)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: Professor Joy Ardill
#878 Evidence of Improved Survival When Patients are Referred on to a Specialist NET Clinic with Multidisciplinary Team Management
Introduction: ENETs and UKINETs Guidelines emphasize that patients with NETs should be referred to NET specialist clinics (NSC) and these clinics should use a multidisciplinary team (MDT) for decision making. In Belfast there has been an NSC for several decades and an MDT since 2000.
Conference: 11th Annual ENETS Conference (2014)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: Professor Joy E Ardill
Authors: Ardill J E, McCance D, Johnston B, ...
Keywords: NET Clinics
#671 Comparison of the Utility of Biochemical Markers in Predicting the Presence and Severity of Carcinoid Heart Disease
Introduction: Carcinoid heart disease (CHD) is a complication of metastatic neuroendocrine disease and is screened for using echocardiography.
Conference: 10th Annual ENETS Conference (2013)
Category: Biomarkers
Presenting Author: Dr Rebecca Dobson
Authors: Dobson R, Burgess M, Chadwick C, Vora J, ...
#508 Differential Expression of Markers in a Midgut Carcinoid Tissue Microarray
Introduction: Molecular mechanisms driving well-differentiated midgut carcinoid (MGC) tumors are not well-established. To pursue higher resolution tumor diagnostics, we studied a panel of markers for their expression in MGC, including: serotonin, FGF2, b-catenin, and E-cadherin, in primary, lymph node, and liver metastases.
Conference: 9th Annual ENETS Conference (2012)
Category: Basic
Presenting Author: Eric Liu
Authors: Liu E, Mikhitarian K, Revetta F, Shi C, ...
#53 The rise and fall of chromogranin A as an indicator for NET
Introduction: There is now general awareness that treatment with proton pump inhibitors (ppi) may cause moderate rises in circulating concentrations of gastrin and/or chromogranin A (CgA), thus decreasing the specificity of these markers in the diagnosis of neuroendocrine tumors (NETs). Due to their high efficacy, proton pump inhibitors (ppi) are one of the most frequently prescribed classes of drugs worldwide. Several studies in various countries report that 30% or more of in-patients have been prescribed ppi. Patients who are suspected of having a neuroendocrine tumor (NET) often have gastrointestinal (GI) symptoms for which ppi are prescribed and therefore they may be already taking ppi when their first blood sample is assayed for NET markers. We previously encountered a case of extreme rise in CgA which flagged the possibility of a NET, but was later shown to be due to ppi therapy alone. We present CgA and gastrin data in relation to ppi therapy and withdrawal for this patient. In order to see if this was an isolated incident, we audited all laboratory requests for CgA/gastrin in a two-year period and monitored those that provided details of ppi treatment/withdrawal.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Lee Armstrong
Authors: Armstrong L, Ryan K, Ardill J, ...
Close
Notice

WARNING – FRAUDULENT WEBSITES

ENETS is aware that its members have been confronted with fake websites, which seem to relate to our congress but have not been commissioned or authorised by us. The websites offer fraudulent hotel reservation services. We therefore strongly recommend that you please only use the official enetsconference.org website when booking your tickets and accommodation. Please be vigilant when it comes to providing your credit card details. 

If you have any questions, please do not hesitate to contact us at info@enets.org.